Portal de Periódicos da CAPES

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

2017; Elsevier BV; Volume: 129; Issue: 13 Linguagem: Inglês

10.1182/blood-2016-09-736892

1528-0020

Sophia Gayle, Sean F. Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan M. Rothberg, Henri S. Lichenstein,

Calcium signaling and nucleotide metabolism

Key Points Apilimod has broad anticancer activity in vitro and in vivo across all subtypes of B-NHL. Apilimod induces B-NHL cytotoxicity through a unique mechanism of action that involves the disruption of lysosomal function.